Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stuart C Gordon
Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial
The Lancet
Medicine
Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study
American Journal of Gastroenterology
Hepatology
Gastroenterology
Related publications
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Gastroenterology
Hepatology
Gastroenterology
Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection
Eastern Mediterranean Health Journal
Medicine
Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response
Hepatology
Medicine
Hepatology
Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1
American Journal of Gastroenterology
Hepatology
Gastroenterology
Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy
Acta Hepatologica Japonica
Hepatology
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Gastroenterology
Hepatology
Gastroenterology
Mixed Treatment Comparisons to Compare Simeprevir With Boceprevir and Telaprevir in Combination With Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected With Genotype 1 Hepatitis C Virus (Hcv)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PIN50 the Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis From the Perspective of the Scottish National Health Service (NHS)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients With Hepatitis C Virus Genotype 2 or 3
Clinical Medicine and Research
Medicine
Home Care
Community
